1. In Vivo
  2. >>Archive

At APA, Neuronetics Launches TMS

For millions of Americans who suffer from moderate to severe depression-and millions more around the world-existing drug therapies don't provide adequate treatment. For some, the drugs simply don't work; for others, the drugs treat their depression, but their side effects are so debilitating that the cure is worse than the disease. Now, Neuronetics says it has a new approach to depression treatment, one based on the focused delivery of magnetic energy, that works for these otherwise untreatable patients. More importantly, the company claims, it now has the data to prove it.

For millions of Americans who suffer from moderate to severe depression—and millions more around the world—existing drug therapies don't provide adequate treatment. For some, the drugs simply don't work; for others, the drugs treat their depression, but their side effects are so debilitating that the cure is worse than the disease. Now, Neuronetics Inc. , a Philadelphia-based medical device company, says it has a new approach to depression treatment, one based on the focused delivery of magnetic energy, that works for these otherwise untreatable patients. More importantly, the company claims, it now has the data to prove it.

Neuronetics' NeuroStar TMS (transcranial-magnetic stimulation) therapy system is a non-invasive therapy that can, says Bruce Shook, the company's president and...

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.